Physician profile
Jason Wayne Siefferman
NPI 1841440617
$29,046.02
in general payments reported to CMS, 2019-2025
53 companies · $15K in 2025
The $15K reported for 2025 was more than what 96% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $1,584 · 2021: $1,378 · 2022: $1,481 · 2023: $4,303 · 2024: $4,840 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $10K · Consulting Fee: $880 · Education: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,980.00 |
| Food and Beverage | $10,343.25 |
| Consulting Fee | $880.00 |
| Education | $136.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $15,059.17 | 2021-2025 | Xeomin |
| Abbvie INC. | $2,610.14 | 2021-2025 | Botox, Qulipta, Ubrelvy |
| Spr Therapeutics, INC | $1,629.39 | 2020-2024 | Sprint Pns System |
| Boston Scientific Corporation | $1,224.57 | 2021-2025 | Wavewriter Alpha Prime 16 |
| Lundbeck LLC | $951.39 | 2021-2025 | Vyepti |
| Allergan, INC. | $715.15 | 2019-2022 | |
| Abbott Laboratories | $615.38 | 2021-2023 | Proclaim, Axium |
| Ucb, INC. | $595.44 | 2023-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $501.15 | 2023-2025 | Tremfya, Simponi Aria |
| Pfizer INC. | $467.25 | 2023-2025 | |
| Nevro Corp. | $427.66 | 2022 | |
| Medtronic, INC. | $374.73 | 2023-2024 | Intellis Adaptivestim |
| Azurity Pharmaceuticals, INC. | $342.21 | 2023-2025 | Horizant, Horizant |
| Amgen INC. | $289.40 | 2022-2025 | Tavneos, Evenity, Prolia |
| Lilly USA, LLC | $264.35 | 2023-2025 | Emgality, Zepbound, Mounjaro |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Siefferman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.